Group 1 - The announcement states that Chengdu Rongsheng Pharmaceutical Co., Ltd., a subsidiary of Beijing Tiantan Biological Products Co., Ltd., has received the Drug GMP Compliance Inspection Notice from the Sichuan Provincial Drug Administration [1][2] - The inspection was conducted from June 16 to June 19, 2025, and concluded that the production facility complies with the Drug Production Quality Management Standards (2010 revision) [2] - The inspected facility is focused on the production of therapeutic biological products, specifically the injection of recombinant human coagulation factor VIIa [1][2] Group 2 - The product "Injection of Recombinant Human Coagulation Factor VIIa" has completed Phase III clinical trials and has submitted a marketing authorization application, which is currently under review [3] - The receipt of the GMP Compliance Inspection Notice indicates that the production facility meets national GMP requirements, allowing for potential production upon obtaining the registration certificate and final production license for the product [3] - Future production of the product may be influenced by national policies and market conditions, indicating a level of uncertainty [3]

天坛生物公告，下属企业成都蓉生药业有限责任公司收到四川省药品监督管理局颁发的《药品GMP符 合性检查告知书》。证书编号为川许2025169，检查时间为2025年6月16日至6月19日，检查结论为符合 《药品生产质量管理规范（2010年修订）》及相关附录规定。此次获得告知书意味着成都蓉生的重组产 品生产车间符合国家GMP要求，待取得"注射用重组人凝血因子Ⅶa"注册证书和最终生产许可后，即可 实现该产品的生产。 ...

Core Viewpoint - The company is actively expanding its international market presence and enhancing its product offerings while addressing pricing strategies and production efficiency to meet annual targets [1][2]. Group 1: International Expansion and Product Development - The company has established an International Cooperation Department to focus on international market development and registration preparations, successfully exporting several immunoglobulin products [1]. - The company is advancing its key products towards international certification and registration, aiming to become a globally influential blood product enterprise [1]. Group 2: Pricing Strategy and Market Position - In response to investor concerns about declining gross margins due to falling prices of blood products, the management indicated that product prices have stabilized in 2025, although there was a decrease compared to the full year of 2024 [1]. - The company plans to implement multiple measures to achieve its annual goals, including increasing market share, boosting sales, and reducing inventory [1]. Group 3: Research and Development Progress - The company maintains a leading level of R&D investment in the industry, with over ten products under research, including blood products and gene-recombinant products [2]. - Two products have completed Phase III clinical trials and have submitted applications for marketing authorization, while others are progressing well in clinical trials [2]. Group 4: Production Capacity and Facility Development - The Yunnan project has completed key product registration inspections and is currently addressing inspection deficiencies, with plans to accelerate production site transfer for major products [2]. - The Yunnan facility is expected to commence production in 2026, focusing on human albumin, intravenous immunoglobulin, and prothrombin complex products [2].

Group 1 - The company has not launched any new products so far this year [2] - Two new products, "subcutaneous injection of human immunoglobulin" and "recombinant human coagulation factor VIIa for injection," have completed clinical trials and submitted for market approval [2]

Core Viewpoint - The company is preparing for its 2024 annual shareholders' meeting, emphasizing the protection of shareholders' rights and the efficiency of the meeting process [1][2][3]. Meeting Procedures - The board of directors is committed to maintaining order and efficiency during the shareholders' meeting, adhering to relevant laws and regulations [1]. - Shareholders must register according to the meeting notice and present valid identification to attend [1]. - Late arrivals will not be counted in the voting unless approved by the meeting's working group [1]. - Shareholders have the right to speak, consult, and vote during the meeting, and must respect the rights of other shareholders [1][2]. Meeting Agenda - The meeting will cover several key topics, including the review of the 2024 board and supervisory reports, financial statements, and profit distribution plans [3][4]. - The company achieved a revenue of 6.03 billion yuan in 2024, a year-on-year increase of 16.44%, and a net profit of 1.55 billion yuan, up 39.58% [4]. Operational Highlights - The company has focused on enhancing blood source development, achieving a collection of 2,781 tons of plasma in 2024, a 15.15% increase year-on-year [4][5]. - The company has implemented various quality management systems to ensure the safety of plasma donors and the quality of raw plasma [5][6]. - The production of blood products has been optimized through the adoption of advanced information systems, leading to improved efficiency and product yield [5][6]. Research and Development - The company has made significant progress in drug development, with several products completing clinical trials and receiving regulatory approvals [7]. - In 2024, the company was granted 22 patents, including 3 invention patents [7]. Market Strategy - The company is actively expanding its market presence, focusing on pediatric, neurological, and critical care sectors, and has established connections with over 700 top-tier hospitals across more than 30 provinces [8]. - The company is also pursuing international market opportunities, with products registered for sale in Macau and participation in international trade exhibitions [8]. Investment and Growth - The company completed the acquisition of a 100% stake in Zhongyuan Ruide for 185 million USD, adding new plasma collection stations and increasing plasma collection capacity [9][10]. - Ongoing investments in existing plasma stations are aimed at expanding blood source capabilities [10]. Compliance and Governance - The company has established a robust internal control system to ensure compliance with legal and regulatory requirements, enhancing risk management capabilities [10][11]. - The board of directors and supervisory committee have conducted regular meetings to oversee the company's operations and ensure adherence to governance standards [12][19]. Future Plans - The company aims to strengthen budget control, enhance blood source management, optimize production processes, and expand international operations in 2025 [15][16][17].